Notably, MYCN's unique expression profile, predominantly absent in mature tissues but frequently dysregulated in a substantial portion of alveolar rhabdomyosarcoma cases, makes it an enticing target for immunotherapeutic interventions. This evidence concerns the gene MYCN and rhabdomyosarcoma.